Brief: Liminal BioSciences Provides Update On Its Lead Drug Candidate Fezagepras
14/03/2022 12:05
March 14 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES PROVIDES UPDATE ON ITS LEAD DRUG
CANDIDATE
FEZAGEPRAS
* LIMINAL BIOSCIENCES INC - DATA OBSERVED SHOWS THAT
FEZAGEPRAS
HAS NITROGEN SCAVENGING PROPERTIES
* LIMINAL BIOSCIENCES - PLANNED PHASE 1A SINGLE ASCENDING
DOSE
TRIAL, IN Q2 2022, TO COMPARE FEZAGEPRAS WITH SODIUM
PHENYLBUTYRATE AS NITROGEN SCAVENGER
Source text for Eikon: ID:nPn82NgqBa
Further company coverage: LMNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminal BioSciences
See all newsBrief: Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Brief: Liminal Biosciences Files Amended Schedule 13E-3 And Supplement To Management Information Circular
Brief: Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
U.S. STOCKS ON THE MOVE-Liminal Biosciences, Tesla, Quad/Graphics
U.S. STOCKS ON THE MOVE-T2 Biosystems, GoodRx Holdings, ShiftPixy